Articles

The presentation outlines the importance of establishing an integrated approach in evidence generation to deliver a unified value proposition and discusses the challenges that an organisation must overcome when there is not such an approach in place. Finally, we lay out a set of benefits that pharmaceutical companies can realise from establishing of an IEGP

Pharmaceutical companies need to patient and financial value through the development and commercialisation of products. This requires a clear strategy with robust product planning, execution and tracking. The purpose of this presentation is to describe the key elements that need to be considered in order to optimise product strategy and planning.

Regulatory Affairs organisations interface with many internal and external stakeholders and will need to continue to respond to a dynamic and evolving environment. We outline 5 priorities that Regulatory Affairs organisations must explore in order to prepare for the future:​ Enhance the Regulatory Affairs and Pharmacovigilance interface​ Optimise outsourcing ​ Prepare for new modalities​ Drive efficiencies and quality through automation​ Explore machine learning

Technological developments and the ever increasing breadth and depth of new information and evidence being generated have driven many life sciences companies to focus on making information accessible to external stakeholders across multiple channels in a seamless way – often referred to as ‘omnichannel strategy’. However, there is often too much focus on technology and not on the strategic